Triple therapy aims to shrink liver tumors before surgery
NCT ID NCT07014150
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib) before surgery can improve outcomes for people with liver cancer at high risk of recurrence. About 33 participants will receive the drugs for 9 weeks, then have surgery. Researchers will measure how many tumors shrink or disappear and track safety and long-term survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- iparomlimab, tuvonralimab, and lenvatinib
- What this could lead to
- If successful, this combination could shrink liver tumors before surgery and lower the chance of cancer coming back, offering a better treatment path for high-risk patients.
- What could go wrong
- This is a small, early-phase trial with only 33 participants, so results may not apply broadly. The drug combination can cause side effects like fatigue, high blood pressure, or immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA RESECTABLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese Academy of Medical Sciences，Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.